Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | PPIA | P62937 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30768150 | 1.00 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL21736594 | 1.00 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| Cyclo(Prolylglycyl) SCHEMBL3016264 | 1.00 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL21736595 | 1.00 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| Cyclo(Prolylglycyl) SCHEMBL4243772 | 1.00 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL1189351 | 0.94 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL3519704 | 0.94 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL3519708 | 0.94 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL17516644 | 0.93 | KDM4E (0.43) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL464685 | 0.93 | KDM4E (0.43) | ALDH1A1KDM4EMAPTGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319060-A1 | METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19 | TRAN LLOYD HUNG LOI (US) | 2025-10-16 | — | — | US | claimed |
| EP-4594325-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | Novmetapharma Co., Ltd. (KR) | 2025-08-06 | — | — | EP | claimed |
| WO-2025088052-A1 | CYCLIC ANALOGUE OF GLYCINE-PROLINE FOR USE IN THE PREVENTION AND/OR TREATMENT OF MEDICAL IMPLANT-RELATED FIBROSIS | ROUSSELOT BV (BE) | 2025-05-01 | — | — | WO | claimed |
| CN-119770491-A | Application of cycloglycine-proline in preparing medicine for treating binge eating disease | 北京大学 | 2025-04-08 | — | — | CN | claimed |
| CN-119775430-A | Mineral composite peptide and preparation and application thereof | 中国科学院烟台海岸带研究所 | 2025-04-08 | — | — | CN | claimed |
| US-20250049883-A1 | ANIMAL, FUNGAL AND MARINE SOURCES OF CGP AND INCREASED CGP CONCENTRATION FOR DISEASE MANAGEMENT AND FOR TREATMENT OF NON-NEUROLOGICAL AND/OR NEUROLOGICAL CONDITIONS | THE CGP LAB LTD (NZ) | 2025-02-13 | — | — | US | claimed |
| US-12216119-B2 | IGF-1 analysis, adjustment and disease management of non-neurological and/or neurological conditions | THE CGP LAB LIMITED (NZ) | 2025-02-04 | — | — | US | claimed |
| EP-4452270-A1 | ANIMAL, FUNGAL AND MARINE SOURCES OF CGP AND INCREASED CGP CONCENTRATION FOR DISEASE MANAGEMENT AND FOR TREATMENT OF NON-NEUROLOGICAL AND/OR NEUROLOGICAL CONDITIONS | THE CGP LAB LIMITED (NZ) | 2024-10-30 | — | — | EP | claimed |
| CN-118613263-A | CGP of animal, fungal and marine biological origin and increased cGP concentrations for disease management and treatment of non-neurological and/or neurological disorders | CGP实验室有限公司 | 2024-09-06 | — | — | CN | claimed |
| US-20240140955-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | NOVMETAPHARMA CO., LTD. (KR) | 2024-05-02 | — | — | US | claimed |
| WO-2024069524-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | NOVMETAPHARMA CO., LTD. (KR) | 2024-04-04 | — | — | WO | claimed |
| US-20230218596-A1 | METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING CORONAVIRUS INFECTION | MEREO BIOPHARMA 4 LIMITED (GB) | 2023-07-13 | — | — | US | claimed |
| WO-2023113623-A1 | ANIMAL, FUNGAL AND MARINE SOURCES OF CGP AND INCREASED CGP CONCENTRATION FOR DISEASE MANAGEMENT AND FOR TREATMENT OF NON-NEUROLOGICAL AND/OR NEUROLOGICAL CONDITIONS | THE CGP LAB LIMITED (NZ) | 2023-06-22 | — | — | WO | claimed |
| EP-4138906-A1 | METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19 | Tran, Lloyd Hung Loi (US) | 2023-03-01 | — | — | EP | claimed |
| EP-4743102-A1 | COLLAGEN PEPTIDE COMPOSITION AND USE THEREOF IN AMELIORATING NEUROLOGICAL CONDITIONS AND FIBROSIS | Rousselot BV (BE) | 2026-05-20 | — | — | EP | disclosed |
| EP-4714452-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | Gilead Sciences, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4702027-A1 | 4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZINE C-NUCLEOSIDE COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2026-03-04 | — | — | EP | disclosed |
| EP-1513842-A1 | SUBSTITUTED HEXAHYDROPYRROLO (1,2-A)PYRAZINES, OCTAHYDROPYRIDO(1,2-A)PYRAZINES AND DECAHYDROPYRAZINO(1,2-A)AZEPINES | NOVO NORDISK A/S (DK) | 2005-03-16 | — | — | EP | disclosed |
| US-20040023946-A1 | Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines | VTVX HOLDINGS II LLC | 2004-02-05 | — | — | US | disclosed |
| WO-2003104235-A1 | SUBSTITUTED HEXAHYDROPYRROLO[1,2-A]PYRAZINES, OCTAHYDROPYRIDO[1,2-A]PYRAZINES AND DECAHYDROPYRAZINO[1,2-A]AZEPINES | NOVO NORDISK A/S (DK) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023946-A1 | Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines | HRH2, HRH4, HRH1 | ALDH1A1 835/4885KDM4E 1409/4885MAPT 1954/4885 |
| US-20240140955-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | LNPEP, ANPEP, DNPEP | ALDH1A1 1719/4885KDM4E 2288/4885MAPT 3200/4885 |
| US-20250319060-A1 | METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19 | ACE, ACE2, LPO | ALDH1A1 1640/4885KDM4E 1900/4885MAPT 1277/4885 |
| US-20230218596-A1 | METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING CORONAVIRUS INFECTION | SERPINB1, ELANE, MPO | ALDH1A1 3704/4885KDM4E 4221/4885MAPT 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.